Cancer – Non-Small Cell Lung Cancer (NSCLC)

In this episode of the AMCP Unscripted podcast, host Steve Kheloussi, PharmD, principal consultant with Kheloussi Consulting and a managed care pharmacist, is joined by Tianyi Wang, consultant at Omnicom Health Market Access, and Irvin Molina, PharmD, BCOP, director of clinical pharmacy at IPD Analytics and a board-certified oncology pharmacist, to explore how National Comprehensive Cancer Network (NCCN) guidelines influence payer policy and patient access in non-small cell lung cancer (NSCLC).

AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.

Hear from a panel of experts discussing bridging the gaps in precision oncology: opportunities in non-small cell lung cancer

Hear from a panel of experts discussing biomarker testing in non-small cell lung cancer

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.